Horcasitas-Pous RA, Martínez-Lorenzo R

Language: Spanish
References: 6
Page: 7-11
PDF size: 342.88 Kb.

ABSTRACT

Background: Propanolol prescription for the treatment of several solid tumours has been increased lately trying to block VEGF. Respiratory papillomatosis have β adrenergic receptors 1 and 2 that respond theorically to propanolol generating vasoconstriction and decreasing long lasting tumour NO2 levels, extending surgical time results.
Objective: To assess the efficacy of propanolol as adjuvant treatment of respiratory papillomatosis.
Material and Method: A prospective study was done including six patients in the control protocol. All patients were part of the cidofovir protocol at Pediatric Hospital of Chihuahua State, Mexico, with a follow-up of nine months to three years; all patients started treatment with propanolol after the last direct laryngoscopy and administration of cidofovir at dose of 7.5 g total in the injection. All patients had a biopsy of the lesion that confirmed the diagnosis of respiratory papillomatosis and a typification study of the virus by polymerase chain reaction.
Results: Five patients continued the treatment established in the protocol, and one male patient abandoned it due to hypotension and moderate bradichardia during exercise. Two of six patients required a new laryngoscopy and intralesional cidofovir. None patient has had any adverse drug reaction during protocol.
Conclusions: Propanolol is a useful drug as adjuvant treatment of respiratory papillomatosis, is cheap and has little systemic effects.

REFERENCES

1. Derkay CS, Wiatrak B. Recurrent respiratory papillomatosis a review. Laryngosocope 2008;118. 1236-1247.

2. Chisholm K, Chang K, Tuong M. β-Adrenergic receptor expression in vascular tumors. Modern Pathol 2012;25:1446-1451.

3. Maturo S, Man S, Kinane TB, Hartnick CJ. Initial experience using propanolol as an adjuntive treatment in chlidren with agressive recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2011;120:17-20.

4. Katona G, Csákány Z, Gács E, Szalai Z, et al. Propanolol for infantile hemangioma. Striking effect in the first weeks; Int J of Ped Otorhinolaryngology; 2012;76:1746- 1750.

5. Rahbar R, Vargas SO, Folkman J, et al. Role of vascular endothelial grown factor-A in recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2005;114:289- 295.

6. Artman M, Grayson M, Boerth RC, et al. Propanolol in children: safety-toxicity. Pediatrics 1982:70:30-31.